Results Relief of pain symptoms Pain was the presenting symptom in 57.1% (8/14) of patients prior to treatment. Following125I seed implantation, the RR was 87.5% (7/8), two of patients with severe pain become no pain, two of patients with severe pain become mild pain, one of patients with severe pain became moderate, two of patients with moderate pain became no pain and one of patients with moderate became mild pain. Most patients experienced pain relief

within one week following seed implantation. Local control and survival The response rate of tumor was 78.6%, overall local control rates in this study were 78.6% (11/14) (Figure 2) too. The overall median survival was 10 months (95% CI, 7.6–12.3), while the overall 1-, 2- and 3-year survival rates were 33.9%, 16.9% and 7.8%, respectively. R406 supplier The Kaplan-Meier actuarial survival curve of all 14 patients treated with seed implantation is shown in Figure 3. Seven patients died of metastases to the liver and peritoneal surface, yet had no image evidence of any residual local disease.

Two patients died of local progression, two patients died of local P5091 progression and metastases, one patient died of heart disease. Figure 2 Actuarial local control curve for 14 patients treated with 125 I seed implantation. Figure 3 Actuarial survival curve for 14 patients with unresected stage II/III pancreatic carcinoma treated with 125 I seed implantation. Toxicity and complications No patient died during the perioperative period, although chylous

fistula was observed in one patient (7%). One patient (7%) who underwent both seed implantation and EBRT developed a gastric ulcer. One patient (7%) experienced radiation enteritis and 7 (50%) patients experienced fever. Clinical evaluation, ultrasound, and CT scans determined that the majority of patients developed metastases to the selleck screening library liver and peritoneal surface. Additionally, for 2 (14%) patients, three seeds were found to have migrated to the liver in each case. However, no side effects were observed for 12-months post-treatment. Discussion The treatment of unresectable pancreatic cancer continues to be a major challenge. More than half of patients have a locally or regionally confined tumor requiring local treatment. Stereotactic radiotherapy (SRT) allows an escalation of radiation doses to be applied to a small target volume within a small margin. SRT is administered in one or a few fractions with the goal of sparing the surrounding normal Selleck Pictilisib tissue by using multiple non-coplanar field arrangements for the administration. In a phase II study on the use of SRT in the treatment of locally advanced pancreatic carcinoma by Huyer et al, the median survival time was only 5.7 months, and the one-year survival rate was 5% [17]. These data associate SRT with a poor outcome, unacceptable toxicity, and questionable palliative effects, making SRT unadvisable for patients with advanced pancreatic carcinoma.